Posted by Michael Wonder on 23 Aug 2022
Menarini Group’s elacestrant marketing authorisation application accepted for review by the EMA for the treatment of ER+/HER2- advanced or metastatic breast cancer
19 August 2022 - Elacestrant, if approved, would be the first oral selective oestrogen receptor degrader to be available for patients suffering from second-line and third-line ER+/HER2- advanced or metastatic breast cancer in the European Union.
The Menarini Group and Stemline Therapeutics today announced that EMA has validated the marketing authorisation application for elacestrant, a selective oestrogen receptor degrader, for patients with ER+/HER2- advanced or metastatic breast cancer.
